HCPCS Level II Q5134: Injection, natalizumab-sztn (Tyruko), biosimilar, 1 mg
HCPCS Level II code Q5134 represents the injection product natalizumab-sztn (Tyruko), a biosimilar formulation of natalizumab supplied in a 1 mg unit; service type is therapeutic monoclonal antibody injection typically administered in infusion clinic or outpatient infusion center settings for patients requiring natalizumab therapy.
For related coverage guidance, see recent payer policy updates: Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Prevention and Treatment, HIV/AIDS Pharmacologic Prevention and Treatment, Long-Acting Injectable Antiretroviral Agents for HIV.
Customize your policy alerts
Sign up for hcpcs Q5134 policy alerts
Get alerted when payer policies referencing Q5134 are released or updated.
Monitor payer policy activity